Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 5/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569369 | 1.00 | HSD11B1 (0.58) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL3710751 | 0.95 | HSD11B1 (0.53) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL3710748 | 0.95 | HSD11B1 (0.53) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL3713502 | 0.94 | HSD11B1 (0.52) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL3713499 | 0.94 | HSD11B1 (0.52) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL9105680 | 0.90 | HSD11B1 (0.49) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL9105684 | 0.90 | HSD11B1 (0.49) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL3427330 | 0.90 | GBA1 (0.47) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL3427328 | 0.90 | GBA1 (0.47) | HSD11B1CNR1CNR2GBA1GRM2 | |
| SCHEMBL352377 | 0.88 | GRM2 (0.44) | HSD11B1CNR1CNR2GRM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2384320-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HSD11B1 3537/4885CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.